Dr. Fred Moll 

During his surgical residency at Virginia Mason Medical Center in the early 1980s, Moll says he was “struck by the size of the incision and injury created just to get inside the body.” He left his residency to develop the safety trocar, which helped make general laparoscopic surgery possible, and funded - and later sold - two medical equipment businesses in Silicon Valley: Endotherapeutics (acquired by United States Surgical) and Origin Medsystems (acquired by Eli Lilly). He also obtained an M.S. degree in business management from Stanford University.

Following its acquisition by Eli Lilly, Origin MedSystem became an operating company within Guidant in 1992. Moll served as medical director of Guidant's surgical division until 1995. During this time, he became certain that robotics could help to make routine surgery less invasive, and in 1995 left Guidant to found Intuitive Surgical with John Freund and Rob Younge. Since this time, Intuitive has worked on developing minimally-invasive, robotic assisted tools and platforms, including the da Vinci system for robotic-assisted surgical procedures.

Moll left Intuitive Surgical in 2002 to become founder & CEO of Hansen Medical, which developed robotic systems for vascular and interventional electrophysiology procedures, and a robotically steered catheter sheath. Hansen Medical received Frost & Sullivan's Product Innovation Award in 2008 for US Image-Guided and Robotic Assisted Surgery Devices.

Moll was a board member of Mako Surgical until its sale in 2013.

Moll co-founded surgical robotics company Auris Surgical Robots, now Auris Health, with Hari Sundram and J.P Velis in 2007. Auris Health's Monarch system is a diagnostic tool that uses robotic-assisted endoscopy. Its application in the earlier and more accurate diagnosis of lung cancer was approved by the FDA in 2018. Johnson & Johnson (J&J) announced its acquisition of Auris Health in February 2019; Moll joined J&J as Chief Development Officer as part of the acquisition, and was involved in the acquisition of Verb Surgical from Alphabet Inc.'s Verily Life Sciences at the end of 2019.

From April 2019 to March 2023, Dr. Moll served as Chief Development Officer for Johnson & Johnson Medical Devices Companies. Dr. Moll was also a co-founder, and, from September 2012 to 2019, was the Chairman and Chief Executive Officer of Auris Health, Inc., a robotics medical device company, that was acquired by Johnson and Johnson in 2019.

Dr. Moll is also the Founding Partner of Sonder Capital Management, LLC, a healthcare venture capital investment firm. He serves on the boards of Procept BioRobotics since August 2011 and has served as Chair since March 2021, Shockwave Medical, Inc., since March 2011, where he is a member of the nominating and corporate governance committee, and INSIGHTEC Ltd., since June 2020, where he is a member of the audit committee.

Dr. Moll previously served as member and as Chairman of the board of Restoration Robotics, Inc., from November 2002 until its merger with Venus Concept in November 2019. Dr. Moll previously served on the board of directors at Intersect ENT, Inc. from March 2010 to February 2021, where he was a member of the nominating and corporate governance committee.

Dr. Moll received a B.A. in economics from the University of California at Berkeley, an M.S. in management from Stanford University and an M.D. from the University of Washington.